Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a research report issued on Wednesday. They presently have a $87.00 price objective on the stock. Wedbush’s price target would suggest a potential upside of 76.83% from the stock’s current price.

A number of other analysts have also recently commented on the company. Cowen and Company reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Friday, July 14th. BidaskClub raised Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th. Royal Bank Of Canada set a $58.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, June 27th. ValuEngine raised Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 20th. Finally, Canaccord Genuity set a $60.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, May 22nd. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $55.25.

Shares of Pacira Pharmaceuticals (PCRX) opened at 49.20 on Wednesday. The firm’s 50-day moving average price is $46.49 and its 200 day moving average price is $45.20. The stock’s market cap is $1.97 billion. Pacira Pharmaceuticals has a 1-year low of $29.95 and a 1-year high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Thursday, May 4th. The company reported ($0.19) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.04. Pacira Pharmaceuticals had a negative return on equity of 7.71% and a negative net margin of 19.26%. The business had revenue of $69.30 million for the quarter, compared to analysts’ expectations of $70.30 million. During the same quarter in the previous year, the firm earned $0.15 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year.

ILLEGAL ACTIVITY NOTICE: “Pacira Pharmaceuticals, Inc. (PCRX) Given Outperform Rating at Wedbush” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/07/19/pacira-pharmaceuticals-inc-pcrx-given-outperform-rating-at-wedbush.html.

In related news, CAO Kristen Marie Williams sold 21,041 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $50.86, for a total transaction of $1,070,145.26. Following the completion of the transaction, the chief accounting officer now directly owns 18,775 shares in the company, valued at approximately $954,896.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David M. Stack sold 4,311 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $43.32, for a total value of $186,752.52. Following the transaction, the chief executive officer now owns 59,559 shares of the company’s stock, valued at $2,580,095.88. The disclosure for this sale can be found here. Insiders have sold a total of 50,564 shares of company stock valued at $2,506,682 over the last 90 days. Insiders own 6.60% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new position in shares of Pacira Pharmaceuticals during the fourth quarter valued at $256,000. Renaissance Technologies LLC increased its position in shares of Pacira Pharmaceuticals by 1.6% in the fourth quarter. Renaissance Technologies LLC now owns 25,200 shares of the company’s stock valued at $814,000 after buying an additional 400 shares during the period. Numeric Investors LLC acquired a new position in shares of Pacira Pharmaceuticals during the fourth quarter valued at $239,000. Norges Bank acquired a new position in shares of Pacira Pharmaceuticals during the fourth quarter valued at $13,258,000. Finally, Teachers Advisors LLC increased its position in shares of Pacira Pharmaceuticals by 6.2% in the fourth quarter. Teachers Advisors LLC now owns 62,854 shares of the company’s stock valued at $2,030,000 after buying an additional 3,658 shares during the period.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.